Published: 30 March 2021
Author(s): Ji Hyun Lee, Beom Kyung Kim, Soo Young Park, Won Young Tak, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Dong Hyun Sinn, Seung Up Kim
Issue: May 2021

Whether entecavir (ETV) or tenofovir disoproxil fumarate (TDF) affords the better prognosis after curative treatment of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains unclear. We compared recurrence and death rates between patients taking ETV and those taking TDF.

Newsletters

Stay informed on our latest news!